Immunoglobulins and complement factors in senile plaques: An immunoperoxidase study
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Immunoperoxidase techniques were used to obtain information about the possible presence of serum factors in senile plaques. We found only in plaques consisting of an amyloid core surrounded by a corona of degenerating neurites small amounts of IgG and light chains (kappa and lambda). These immunoglobulins were principally localized in the corona and not in the central amyloid core. Further it was found that all plaques contain the complement factors C1q, C3b, C3c, C3d and C4. Senile plaques lacked C5, C3 pro-activator and properdin. The possible significance of these findings in the genesis of the senile plaques and amyloid formation is discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Activated microglia along with immunoglobulins and complement components are closely associated with Aβ deposits in brains from AD patients and AD mouse models (58)(59)(60)(61)(62).”
From Microglia in Alzheimer's disease (2017) · cites this paper as [58]
Citations
Cites
Histochemistry: Theoretical and Applied
(1953) · Journal of the American Medical Association · doi:10.1001/jama.1953.02940280072039 · Cited by 7,021
ON THE BINDING OF CONGO RED BY AMYLOID
PUCHTLER, H., SWEAT, F., & LEVINE, M. (1962) · Journal of Histochemistry & Cytochemistry · doi:10.1177/10.3.355 · Cited by 1,128
Peroxidase labelled antibody and Fab conjugates with enhanced intracellular penetration
Avrameas, S., & Ternynck, T. (1971) · Immunochemistry · doi:10.1016/0019-2791(71)90395-8 · Cited by 862
Kaplan, M. H., & Volanakis, J. E. (1974) · PubMed · Cited by 563
Glynn, L. E. (1981) · PubMed Central · Cited by 412
Interaction of C-Reactive Protein Complexes with the Complement System
Kaplan, M. H., & Volanakis, J. E. (1974) · The Journal of Immunology · doi:10.4049/jimmunol.112.6.2135 · Cited by 405
ALZHEIMER'S DISEASE AND RELATED DISORDERS
Raskind, M. A., & Peskind, E. R. (2001) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70341-2 · Cited by 161
Immuno-electron microscopic localization of immunoglobulins in amyloid fibrils of senile plaques
Ishii, T., & Haga, S. (1976) · Acta Neuropathologica · doi:10.1007/bf00685368 · Cited by 142
Ishii, T., Haga, S., & Shimizu, F. (1975) · Acta Neuropathologica · doi:10.1007/bf00689569 · Cited by 110
Research works printed but not linked: 6
- Boorsma DM, Streefkerk JG (1978) Improved method for separation of peroxidase conjugates. In: Knapp W, Holubar, K, Wick G (eds) Immunofluorescence and related staining techniques. Elsevier-North Holland Biochemical Press Amsterdam, pp 225?235
- Boorsma DM, Streefkerk JG (1976a) Some aspects of the preparation, analysis and use of peroxidase-antibody conjugates in immunohistochemistry. In: Pecters H (ed) Protides of the biological fluids, vol 24. Pergamon Press, Oxford, pp 795?802
- Davis BJ, Ornstein L (1959) High resolution enzyme localization with a new diazo reagent, ?hexazonium Pararosaniline?. J Histochem Cytochem 7:297?298
- Divry P (1927) Etude histochimique des plaques seniles. J Belge Nerol 27:643?657
- Stam FC (1965) Histochemistry of the senile involution of the brain. In: Vtn Int Congr Neuropathol Proc. Excerpta Medica, Amsterdam, pp 513?517
- Wigboldus JM (1959) Over de aard en genese van de plaques seniles. Thesis. Dijkstra's Drukkerij N.V., Groningen
Cited by
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Variant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558
Alzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis
Karch, C. M., & Goate, A. M. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.006 · Cited by 1,357
“CR1 is an interesting AD risk gene because expression of complement factors is reportedly upregulated in affected regions of brains with AD (75,76).”
MCGEER, P., & MCGEER, E. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(95)00011-9 · Cited by 1,287
Wyss-Coray (2006) · doi:10.1038/nm1484 · Cited by 1,284
Ageing and neuronal vulnerability
Mattson, M. P., & Magnus, T. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1886 · Cited by 957
Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975
Cerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways
Greenberg, S. M., Bacskai, B. J., Hernandez-Guillamon, M., Pruzin, J., Sperling, R., & van Veluw, S. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0281-2 · Cited by 947
Microglia in Alzheimer's disease
Sarlus, H., & Heneka, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90606 · Cited by 911
“Activated microglia along with immunoglobulins and complement components are closely associated with A β deposits in brains from AD patients and AD mouse models (58–62).”
BackgroundAbraham, C. R., Selkoe, D. J., & Potter, H. (1988) · Cell · doi:10.1016/0092-8674(88)90462-x · Cited by 900
Complement activation by beta-amyloid in Alzheimer disease.
Rogers, J., Cooper, N. R., Webster, S., Schultz, J., McGeer, P. L., Styren, S. D., Civin, W. H., Brachova, L., Bradt, B., & Ward, P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.21.10016 · Cited by 817
Amyloid β-Protein and the Genetics of Alzheimer's Disease
Selkoe, D. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.31.18295 · Cited by 799
Aggregation of vascular risk factors and risk of incident Alzheimer disease
Luchsinger, J. A., Reitz, C., Honig, L. S., Tang, M. X., Shea, S., & Mayeux, R. (2005) · Neurology · doi:10.1212/01.wnl.0000172914.08967.dc · Cited by 790
“Hypertension is related to increased vascular permeability with protein extravasation (62), a common finding in brain parenchyma in AD (63,64).”
BackgroundRogers, J., Luber-Narod, J., Styren, S. D., & Civin, W. H. (1988) · Neurobiology of Aging · doi:10.1016/s0197-4580(88)80079-4 · Cited by 743
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
“The fibrillar conformation of Aβ seems to be crucial for such activation.(239) In AD patients, Aβ can bind to microglia cells through the CD36-TLR4-TLR6 receptor complex and the NLRP3 inflammatory complex, destroy cells, release inflammationinducing factors, such as TNF-α, and cause immune responses.”
BackgroundNeuroinflammation in Alzheimer disease
Heneka, M. T., van der Flier, W. M., Jessen, F., Hoozemanns, J., Thal, D. R., Boche, D., Brosseron, F., Teunissen, C., Zetterberg, H., Jacobs, A. H., et al. (2025) · Nature Reviews Immunology · doi:10.1038/s41577-024-01104-7 · Cited by 638
“It has been known for over four decades that the complement components C1q and C3 are associated with pathological hallmarks of AD (plaques and tangles) 6,448,449 .”
InfluentialRisk factors for Alzheimer’s disease
A. Armstrong, R. (2019) · Folia Neuropathologica · doi:10.5114/fn.2019.85929 · Cited by 606
“Hence, complement proteins associated with the ‘classical’ pathway [141], brain reactive antibodies [128], immunoglobulins [46,88], circulating immune complexes (CIC) in peripheral tissue and cerebral blood vessels [73], helper/inducer and cytotoxic/suppressor T-cells [128], and abundant reactive microglia [128] have…”
BackgroundMicroglia in degenerative neurological disease
McGeer, P. L., Kawamata, T., Walker, D. G., Akiyama, H., Tooyama, I., & McGeer, E. G. (1993) · Glia · doi:10.1002/glia.440070114 · Cited by 596
Cribbs, D. H., Berchtold, N. C., Perreau, V., Coleman, P. D., Rogers, J., Tenner, A. J., & Cotman, C. W. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-179 · Cited by 499
“on microglia, and evidence of complement activation within thioflavin-positive neuritic plaques [2,55,56,121,122].”
BackgroundThe amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy
McGeer, P. L., & McGeer, E. G. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1177-7 · Cited by 467
Amyloid β-protein deposition in tissues other than brain in Alzheimer's disease
Joachim, C. L., Mori, H., & Selkoe, D. J. (1989) · Nature · doi:10.1038/341226a0 · Cited by 462
Immune System Response in Alzheimer's Disease
McGeer, P. L., Akiyama, H., Itagaki, S., & McGeer, E. G. (1989) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100029863 · Cited by 459
Isolation of Low‐Molecular‐Weight Proteins from Amyloid Plaque Fibers in Alzheimer's Disease
Selkoe, D. J., Abraham, C. R., Podlisny, M. B., & Duffy, L. K. (1986) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1986.tb08501.x · Cited by 450
Johnson, L. V., Leitner, W. P., Rivest, A. J., Staples, M. K., Radeke, M. J., & Anderson, D. H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192203399 · Cited by 447
Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches
Behl, C. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00055-0 · Cited by 445
Veerhuis, R., Nielsen, H. M., & Tenner, A. J. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2011.04.003 · Cited by 419
“Role of toll- like receptor signalling in Abeta uptake and clearance.”
BackgroundInfluentialActivation of the classical complement pathway in brain tissue of Alzheimer patients
McGeer, P. L., Akiyama, H., Itagaki, S., & McGeer, E. G. (1989) · Neuroscience Letters · doi:10.1016/0304-3940(89)90843-4 · Cited by 383
Complement in neurological disorders and emerging complement-targeted therapeutics
Dalakas, M. C., Alexopoulos, H., & Spaeth, P. J. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0400-0 · Cited by 363
Complement components of the innate immune system in health and disease in the CNS
Gasque, P., Dean, Y. D., McGreal, E. P., VanBeek, J., & Morgan, B. P. (2000) · Immunopharmacology · doi:10.1016/s0162-3109(00)80302-1 · Cited by 343
Up-Regulated Production and Activation of the Complement System in Alzheimer's Disease Brain
Yasojima, K., Schwab, C., McGeer, E. G., & McGeer, P. L. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65340-0 · Cited by 327
Weiner, H. L., Lemere, C. A., Maron, R., Spooner, E. T., Grenfell, T. J., Mori, C., Issazadeh‐Navikas, S., Hancock, W. W., & Selkoe, D. J. (2000) · PubMed · Cited by 310
Rebeck, G. W., Harr, S. D., Hyman, B. T., & Strickland, D. K. (1995) · Annals of Neurology · doi:10.1002/ana.410370212 · Cited by 232
Update on hypertension and Alzheimer's disease
Skoog, I., & Gustafson, D. (2006) · Neurological Research · doi:10.1179/016164106x130506 · Cited by 294
Complement activation in amyloid plaques in Alzheimer’s dementia
Eikelenboom, P., Hack, C. E., Rozemuller, J. M., & Stam, F. C. (1988) · Virchows Archiv B Cell Pathology Including Molecular Pathology · doi:10.1007/bf02890024 · Cited by 288
Self-citationThe good, the bad, and the opportunities of the complement system in neurodegenerative disease
Schartz, N. D., & Tenner, A. J. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02024-8 · Cited by 286
Haga, S., Akai, K., & Ishii, T. (1989) · Acta Neuropathologica · doi:10.1007/bf00687883 · Cited by 286
“In previous immunohistochemical studies, some components of immunoglobulin [7, 19, 32], complement factors [7, 19] and e 1-antichymotrypsin [1 ] have been demonstrated in association with amyloid of senile plaques.”
BackgroundUpadhya, R., Zingg, W., Shetty, S., & Shetty, A. K. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.017 · Cited by 282
Parallel findings in age-related macular degeneration and Alzheimer’s disease
Ohno-Matsui, K. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.02.004 · Cited by 280
“…al., 2005; Johnson et al., 2002, 2001, 2006; Mullins et al., 2000; Nozaki et al., 2006; Umeda et al., 2005; Wang et al., 2010) and senile plaques (Eikelenboom and Stam, 1982; Eikelenboom and Veerhuis, 1996; McGeer et al., 1989; McGeer and McGeer, 1992; Reichwald et al., 2009; Ricchieri et al.,…”
BackgroundThe significance of neuroinflammation in understanding Alzheimer’s disease
Eikelenboom, P., Veerhuis, R., Scheper, W., Rozemuller, A. J. M., van Gool, W. A., & Hoozemans, J. J. M. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0575-6 · Cited by 262
“…the nidus of a chronic inflammatory response In 1982, we demonstrated in an immunohistochemical study that senile plaques contain the early complement factors C1q, C3 and C4 and these findings were confirmed by others (Eikelenboom and Stam, 1982; Ishii and Haga, 1984; Pouplard and Emile, 1985).”
BackgroundSelf-citationWeiner, H. L., Lemere, C. A., Maron, R., Spooner, E. T., Grenfell, T. J., Mori, C., Issazadeh, S., Hancock, W. W., & Selkoe, D. J. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200010)48:4<567::aid-ana3>3.0.co;2-w · Cited by 263
Complement-dependent Proinflammatory Properties of the Alzheimer's Disease β-Peptide
Bradt, B. M., Kolb, W. P., & Cooper, N. R. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.3.431 · Cited by 255
Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia
Grundke-Iqbal, I., Fleming, J., Tung, Y. C., Lassmann, H., Iqbal, K., & Joshi, J. G. (1990) · Acta Neuropathologica · doi:10.1007/bf00334497 · Cited by 253
“outside the areas of the plaques in AD patients and aged controls [1, 4].”
BackgroundResultCyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain
Hoozemans, J. J. M., Rozemuller, A. J. M., Janssen, I., De Groot, C. J. A., Veerhuis, R., & Eikelenboom, P. (2001) · Acta Neuropathologica · doi:10.1007/s004010000251 · Cited by 246
Self-citationExtracellular protein components of amyloid plaques and their roles in Alzheimer’s disease pathology
Rahman, M. M., & Lendel, C. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00465-0 · Cited by 239
Skoog, I., Wallin, A., Fredman, P., Hesse, C., Aevarsson, O., Karlsson, I., Gottfries, C. G., & Blennow, K. (1998) · Neurology · doi:10.1212/wnl.50.4.966 · Cited by 241
Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders
Loeffler, D. A., LeWitt, P. A., Juneau, P. L., Sima, A. A. F., Nguyen, H.-U., DeMaggio, A. J., Brickman, C. M., Brewer, G. J., Dick, R. D., Troyer, M. D., et al. (1996) · Brain Research · doi:10.1016/s0006-8993(96)00782-2 · Cited by 236
Inflammation, anti-inflammatory agents and Alzheimer disease: The last 12 years
McGeer, P. L., Rogers, J., & McGeer, E. G. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9s330 · Cited by 227
“It had previously been shown that the complement system was activated in AD [7] but antibodies, which were then considered to be the main activators of complement, could not be identified in association with AD lesions.”
Localization and Cell Association of C1q in Alzheimer's Disease Brain
Afagh, A., Cummings, B. J., Cribbs, D. H., Cotman, C. W., & Tenner, A. J. (1996) · Experimental Neurology · doi:10.1006/exnr.1996.0043 · Cited by 224
Beyreuther, K., & Masters, C. L. (1991) · Brain Pathology · doi:10.1111/j.1750-3639.1991.tb00667.x · Cited by 221
The Aging Eye: Common Degenerative Mechanisms Between the Alzheimer's Brain and Retinal Disease
Sivak, J. M. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.12-10827 · Cited by 220
Review article What causes alzheimer’s disease?
A. Armstrong, R. (2013) · Folia Neuropathologica · doi:10.5114/fn.2013.37702 · Cited by 217
“Complement proteins associated with the ‘classical’ pathway [123], brain reactive antibodies [132], immunoglobulins [62,95], circulating immune complexes (CIC) in peripheral tissue and cerebral blood vessels [86], helper/inducer and cytotoxic/ suppressor T-cells [123], and abundant reactive microglia [123] have all be…”
BackgroundPodlisny, M. B., Tolan, D. R., & Selkoe, D. J. (1991) · PubMed Central · Cited by 217
Van BEEK, J., ELWARD, K., & GASQUE, P. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb03138.x · Cited by 218
Inflammation, Antiinflammatory Agents, and Alzheimer’s Disease: The Last 22 Years
McGeer, P. L., Rogers, J., & McGeer, E. G. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-160488 · Cited by 215
Complement in the pathogenesis of Alzheimer’s disease
Morgan, B. P. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-017-0662-9 · Cited by 194
The role of complement and activated microglia in the pathogenesis of Alzheimer's disease
Eikelenboom, P., & Veerhuis, R. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(96)00108-x · Cited by 206
Self-citationBrelstaff, J., Tolkovsky, A. M., Ghetti, B., Goedert, M., & Spillantini, M. G. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.072 · Cited by 195
“A role for innate immune factors has long been acknowledged in Alzheimer’s disease (AD) (Eikelenboom and Stam, 1982) and some tauopathies (Singhrao et al.”
Characterization of Apolipoprotein J-Alzheimer's Aβ Interaction
Matsubara, E., Frangione, B., & Ghiso, J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7563 · Cited by 153
Stoltzner, S. E., Grenfell, T. J., Mori, C., Wisniewski, K. E., Wisniewski, T. M., Selkoe, D. J., & Lemere, C. A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64753-0 · Cited by 187
Biology of Aβ Amyloid in Alzheimer's Disease
Wisniewski, T., Ghiso, J., & Frangione, B. (1997) · Neurobiology of Disease · doi:10.1006/nbdi.1997.0147 · Cited by 134
Targeting microglia for the treatment of Alzheimer’s Disease
Wes, P. D., Sayed, F. A., Bard, F., & Gan, L. (2016) · Glia · doi:10.1002/glia.22988 · Cited by 185
“…are also present in AD brains, including alterations in the morphology and distribution of microglia and astrocytes, increased expression of inflammatory mediators, and deposition of complement (Beach et al., 1989; Eikelenboom and Stam, 1982; Itagaki et al., 1989; Wisniewski and Terry, 1973).”
BackgroundBlood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors
Blennow, K., Wallin, A., Fredman, P., Karlsson, I., Gottfries, C. G., & Svennerholm, L. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1990.tb01563.x · Cited by 185
Fu, H., Liu, B., Frost, J. L., Hong, S., Jin, M., Ostaszewski, B., Shankar, G. M., Costantino, I. M., Carroll, M. C., Mayadas, T. N., et al. (2012) · Glia · doi:10.1002/glia.22331 · Cited by 180
Can oral infection be a risk factor for Alzheimer's disease?
Olsen, I., & Singhrao, S. K. (2015) · Journal of Oral Microbiology · doi:10.3402/jom.v7.29143 · Cited by 180
“GWAS now implicates innate 153 immune genes (44, 51 ) as being a risk factor and supports a primary role for th e inflammatory 154 elements of AD pathology via inappropriate activation of the complemen t system (52-54) in 155 association with Aβ plaques and NFTs (55 ).”
BackgroundTeixeira, F. B., Saito, M. T., Matheus, F. C., Prediger, R. D., Yamada, E. S., Maia, C. S. F., & Lima, R. R. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00327 · Cited by 174
“Interestingly, a considerable worldwide population is affected by periodontal diseases, that are oral infections that affect teeth supporting tissues (Dye, 2012; Eke et al., 2015; Oppermann et al., 2015).”
BackgroundColocalization of cholinesterases with ? amyloid protein in aged and Alzheimer's brains
Mor�n, M. A., Mufson, E. J., & G�mez-Ramos, P. (1993) · Acta Neuropathologica · doi:10.1007/bf00334445 · Cited by 172
“In addition, A[SP is associated with serum amyloid P component [17, 19], chromogranin A [45], complement factors Clq, C3c and C3d [20, 21, 25, 41, 51], and protein kinase C”
BackgroundImmuno-electron-microscopic localization of complements in amyloid fibrils of senile plaques
Ishii, T., & Haga, S. (1984) · Acta Neuropathologica · doi:10.1007/bf00687336 · Cited by 172
Brink, B. P., Veerhuis, R., Breij, E. C. W., van der Valk, P., Dijkstra, C. D., & Bö, L. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.2.147 · Cited by 191
“Consistent with previous studies, amyloid plaques in cerebral cortex from Alzheimer disease brain were immunopositive for C1q, C3d, and C4d antibodies, with a much lower intensity of staining for C5b-9 antibodies (32, 33) (data not shown).”
BackgroundResultUltrastructural morphology of amyloid fibrils from neuritic and amyloid plaques
Merz, P. A., Wisniewski, H. M., Somerville, R. A., Bobin, S. A., Masters, C. L., & Iqbal, K. (1983) · Acta Neuropathologica · doi:10.1007/bf00685355 · Cited by 171
Sulfated glycoprotein 2: new relationships of this multifunctional protein to neurodegeneration
May, P. C., & Finch, C. E. (1992) · Trends in Neurosciences · doi:10.1016/0166-2236(92)90190-j · Cited by 170
Wes, P. D., Holtman, I. R., Boddeke, E. W. G. M., Möller, T., & Eggen, B. J. L. (2016) · Glia · doi:10.1002/glia.22866 · Cited by 167
Nrf2 Suppresses Oxidative Stress and Inflammation in App Knock-In Alzheimer’s Disease Model Mice
Uruno, A., Matsumaru, D., Ryoke, R., Saito, R., Kadoguchi, S., Saigusa, D., Saito, T., Saido, T. C., Kawashima, R., & Yamamoto, M. (2020) · Molecular and Cellular Biology · doi:10.1128/mcb.00467-19 · Cited by 166
Early and Late CNS Inflammation in Alzheimer’s Disease: Two Extremes of a Continuum?
Cuello, A. C. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.07.005 · Cited by 165
Brain Microvascular Changes in Alzheimer's Disease and Other Dementiasa
BUÉE, L., HOF, P. R., & DELACOURTE, A. (1997) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1997.tb48457.x · Cited by 165
Clearance of Amyloid-β Peptides By Microglia and Macrophages: the Issue of What, When and Where
Lai, A. Y., & McLaurin, J. (2012) · Future Neurology · doi:10.2217/fnl.12.6 · Cited by 162
Genetics ignite focus on microglial inflammation in Alzheimer’s disease
Malik, M., Parikh, I., Vasquez, J. B., Smith, C., Tai, L., Bu, G., LaDu, M. J., Fardo, D. W., Rebeck, G. W., & Estus, S. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0048-1 · Cited by 161
SP-40,40 is a constituent of Alzheimer's amyloid
Choi-Miura, N. H., Ihara, Y., Fukuchi, K., Takeda, M., Nakano, Y., Tobe, T., & Tomita, M. (1992) · Acta Neuropathologica · doi:10.1007/bf00296787 · Cited by 158
Tacnet‐Delorme, P., Chevallier, S., & Arlaud, G. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.11.6374 · Cited by 178
Veerhuis, R., Janssen, I., Groot, C. J. A. D., Muiswinkel, F. L. V., Hack, C. E., & Eikelenboom, P. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7199 · Cited by 154
Self-citationGuo, J.-T., Yu, J., Grass, D., de Beer, F. C., & Kindy, M. S. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-14-05900.2002 · Cited by 173
“Immunocytochemical analyses have found a variety of inflammatory proteins closely associated with senile plaques (Eikelenboom and Stam, 1982; Abraham et al., 1988; Rogers et al., 1992; Smith et al., 1994; Yan et al., 1996; Selkoe, 1999).”
Backgroundde Jong, D., Jansen, R. W. M. M., Hoefnagels, W. H. L., Mj, J.-E., Verbeek, M. M., Borm, G. F., & Kremer, B. P. H. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001475 · Cited by 159
“[1] Many studies followed that supported the inflammatory hypothesis, and evidence accumulated that anti-inflammatory drugs, in particular nonsteroidal anti-inflammatory drugs (NSAIDs) would either prevent, postpone or treat AD.”
BackgroundAbraham, C. R., Shirahama, T., & Potter, H. (1990) · Neurobiology of Aging · doi:10.1016/0197-4580(90)90045-2 · Cited by 150
Mhatre, M., Floyd, R. A., & Hensley, K. (2004) · Journal of Alzheimer s Disease · doi:10.3233/jad-2004-6206 · Cited by 158
“The reports showing a reduced risk of AD in chronic NSAID users led to numerous research reports showing the evidence for neuroinflammation in AD brain (e.g. [ 20,61–63]).”
The amyloid plaque proteome in early onset Alzheimer’s disease and Down syndrome
Drummond, E., Kavanagh, T., Pires, G., Marta-Ariza, M., Kanshin, E., Nayak, S., Faustin, A., Berdah, V., Ueberheide, B., & Wisniewski, T. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01356-1 · Cited by 137
Evolution of neuroinflammation across the lifespan of individuals with Down syndrome
Flores-Aguilar, L., Iulita, M. F., Kovecses, O., Torres, M. D., Levi, S. M., Zhang, Y., Askenazi, M., Wisniewski, T., Busciglio, J., & Cuello, A. C. (2020) · Brain · doi:10.1093/brain/awaa326 · Cited by 138
Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer’s disease
Zhou, J., Fonseca, M. I., Pisalyaput, K., & Tenner, A. J. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05558.x · Cited by 130
Heparin-binding Properties of the Amyloidogenic Peptides Aβ and Amylin
Watson, D. J., Lander, A. D., & Selkoe, D. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.50.31617 · Cited by 145
Yang, L., Li, R., Meri, S., Rogers, J., & Shen, Y. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-20-07505.2000 · Cited by 135
Haga, S., Ikeda, K., Sato, M., & Ishii, T. (1993) · Brain Research · doi:10.1016/0006-8993(93)91698-r · Cited by 136
Singhrao, S. K., Neal, J., Rushmere, N. K., Morgan, B. P., & Gasque, P. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64604-4 · Cited by 134
Animal models of Alzheimer disease: historical pitfalls and a path forward
Cavanaugh, S. E. (2014) · ALTEX · doi:10.14573/altex.1310071 · Cited by 132
“Deposition of Aβ plaques in the brain is also associated with neuronal damage and activation of local astrocytes and microglia, resulting in localized inflammatory responses (Veerhuis, 2011; Eikelenboom and Stam, 1982; Eikelenboom et al., 1989; Eikelenboom and Veerhuis, 1996; Rosenberg, 2005).”
Complement receptor 1 (CR1) and Alzheimer's disease
Crehan, H., Holton, P., Wray, S., Pocock, J., Guerreiro, R., & Hardy, J. (2012) · Immunobiology · doi:10.1016/j.imbio.2011.07.017 · Cited by 129
Iwamoto, N., Nishiyama, E., Ohwada, J., & Arai, H. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90035-3 · Cited by 129
Blood-brain barrier leakage in Alzheimer’s disease: From discovery to clinical relevance
Nehra, G., Bauer, B., & Hartz, A. M. S. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108119 · Cited by 127
Wilhelmus, M. M. M., de Waal, R. M. W., & Verbeek, M. M. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-0029-7 · Cited by 144
Tracking neuroinflammation in Alzheimer’s disease: the role of positron emission tomography imaging
Zimmer, E. R., Leuzy, A., Benedet, A. L., Breitner, J., Gauthier, S., & Rosa-Neto, P. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-120 · Cited by 121
“Following a set of classic studies implicating the complement factors C1q, C4 and C3 in the formation of amyloid plaques [6,7], activated microglia and the inflammatory cytokine IL-1 were found to be”
BackgroundPoduslo, J. F., Curran, G. L., Wengenack, T. M., Malester, B., & Duff, K. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0402 · Cited by 131
The relationship between blood pressure and dementia: a review
Skoog, I. G. (1997) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(97)89428-0 · Cited by 129
TLR4 is a link between diabetes and Alzheimer’s disease
Huang, N., Jin, H. D., Zhou, S., Shi, J., & Jin, F. J. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.08.047 · Cited by 126
Metadata
- Authors
- Eikelenboom, P., & Stam, F. C.
- Affiliations
- Vrije Universiteit Amsterdam (NL)
- ORCID
- Eikelenboom, P.
- Venue
- Acta Neuropathologica
- Published
- 1982
- Volume
- 57
- Issue
- 2-3
- Pages
- 239-242
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W2312933856
- Cited by
- 454
- References
- 24
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 15 · 2023: 10 · 2022: 8 · 2021: 12 · 2020: 23 · 2019: 13 · 2018: 13 · 2017: 11 · 2016: 9 · 2015: 7 · 2014: 16 · 2013: 7 · 2012: 11
- FWCI
- 2.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Acta Neuropathologica (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Keywords
- amyloid plaques, Alzheimer's disease, immunoglobulins, complement proteins, amyloid core, neurite degeneration, IgG, kappa light chain, lambda light chain, C1q, C3b, C3c, C3d, C4, C5, properdin, amyloid fibril formation
- MeSH terms
- Alzheimer Disease, Amyloid, Cerebral Cortex, Complement System Proteins, Dementia, Humans, Immunoglobulin G, Immunoenzyme Techniques, Immunoglobulins, Immunoglobulin Fc Fragments, Immunoglobulin gamma-Chains
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.